Of note, as aforementioned the interaction of PTPIP51 and c-Src is severely altered in Her2 amplified breast cancer cells when treated with EGFR/Her2 targeted TKIs, but the interaction of PTPIP51 and its crucial phosphatase PTP1B remains nearly unaffected [50]. The gene discussed is ERBB2; the disease is breast carcinoma.